C1QBP and mesothelioma: The data demonstrate that targeting gC1qR with monoclonal antibody 60.11 reduces cell proliferation in vitro and tumor growth in vivo, associated with increased apoptosis and decreased angiogenesis, and provide proof of concept for further exploration of gC1qR directed therapy in mesothelioma.